Tower Research Capital LLC TRC Has $277,000 Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Tower Research Capital LLC TRC boosted its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 413.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,898 shares of the company's stock after buying an additional 16,826 shares during the period. Tower Research Capital LLC TRC's holdings in Takeda Pharmaceutical were worth $277,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in TAK. Blair William & Co. IL grew its position in Takeda Pharmaceutical by 8.1% in the 4th quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock valued at $162,000 after acquiring an additional 913 shares in the last quarter. Sage Rhino Capital LLC increased its position in shares of Takeda Pharmaceutical by 14.9% during the fourth quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock worth $157,000 after acquiring an additional 1,538 shares during the period. Aaron Wealth Advisors LLC boosted its holdings in Takeda Pharmaceutical by 7.2% in the fourth quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company's stock valued at $331,000 after purchasing an additional 1,670 shares during the period. OLD Mission Capital LLC lifted its stake in Takeda Pharmaceutical by 13.7% in the fourth quarter. OLD Mission Capital LLC now owns 13,977 shares of the company's stock worth $185,000 after acquiring an additional 1,687 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in Takeda Pharmaceutical by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock valued at $69,000 after purchasing an additional 1,770 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Down 5.1 %

Shares of NYSE:TAK traded down $0.77 during midday trading on Thursday, reaching $14.29. The company's stock had a trading volume of 821,065 shares, compared to its average volume of 1,873,426. The business has a 50 day moving average price of $14.90 and a 200 day moving average price of $13.99. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15.43. The firm has a market cap of $45.47 billion, a price-to-earnings ratio of 35.73, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.